Regeneron Pharmaceuticals has reported financial results for the Q3 today. Thanks to the largest number of patients of all time that overspread EYLEA and Dupixent, Regeneron has mastered a good result in their diverse pipeline, and because of this, the company’s core business has achieved another good quarterly growth, said Leonard S. Schleifer, CEO of REGN. After the new agreement, the US will supply another 1.4 million doses of REGEN-COV. And the FDA approved a Biologics License Application for REGEN-COV treatment and prevention for intense review with an action date of mid-April 2022. REGN is surging day by day and has already reached $652.1.
Regeneron announced good results of the third phase of Dupixent trials in chronic spontaneous urticaria and juvenile atopic dermatitis in the Q3. And there was also positive news about the FDA approval for childhood asthma was extended to children aged six. Now let’s compare the financial data for the third quarter of this year and last year: the total income came out as $3,453 and $2,294, which is an increase of 51%; GAAP total revenue increased by 94% ($1,632 in 2021 and $842 in 2020), and GAAP total earnings per share also increased by 94% ($14.33 and $7.39, respectively).